Literature DB >> 27706900

OMIP-037: 16-color panel to measure inhibitory receptor signatures from multiple human immune cell subsets.

Anna C Belkina1, Jennifer E Snyder-Cappione1.   

Abstract

Entities:  

Keywords:  CD160; LAG-3; NK cell; PD-1; T cell; TIGIT; TIM-3; cancer; checkpoint inhibition; iNKT cell; immune cell; inhibitory receptors; tumor; γδ T cell

Mesh：

Substances：

Year:  2016        PMID： 27706900     DOI： 10.1002/cyto.a.22983

Source DB:  PubMed          Journal:  Cytometry A        ISSN： 1552-4922            Impact factor:   4.355


× No keyword cloud information.
  4 in total

1.  BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.

Authors:  Guillaume P Andrieu; Jordan S Shafran; Charlotte L Smith; Anna C Belkina; Allison N Casey; Naser Jafari; Gerald V Denis
Journal:  Cancer Lett       Date:  2019-08-29       Impact factor: 8.679

2.  Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.

Authors:  Michelle Fleury; Anna C Belkina; Elizabeth A Proctor; Christopher Zammitti; Robert W Simms; Douglas A Lauffenburger; Jennifer E Snyder-Cappione; Robert Lafyatis; Hans Dooms
Journal:  Arthritis Rheumatol       Date:  2018-03-07       Impact factor: 10.995

3.  HIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction.

Authors:  Hisashi Akiyama; Caitlin M Miller; Chelsea R Ettinger; Anna C Belkina; Jennifer E Snyder-Cappione; Suryaram Gummuluru
Journal:  Nat Commun       Date:  2018-08-27       Impact factor: 14.919

4.  Multivariate Computational Analysis of Gamma Delta T Cell Inhibitory Receptor Signatures Reveals the Divergence of Healthy and ART-Suppressed HIV+ Aging.

Authors:  Anna C Belkina; Alina Starchenko; Katherine A Drake; Elizabeth A Proctor; Riley M F Pihl; Alex Olson; Douglas A Lauffenburger; Nina Lin; Jennifer E Snyder-Cappione
Journal:  Front Immunol       Date:  2018-12-05       Impact factor: 8.786
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.